Olverembatinib in chronic myeloid leukemia: is less actually better?

Affiliations

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Hematology, Faculty of Medicine, University of Toronto, Toronto, ON.
² Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Hematology, Faculty of Medicine, University of Toronto, Toronto, ON. dr.dennis.kim@uhn.ca.

Maria Agustina Perusini et al. Haematologica. 2025.

. 2025 Dec 1;110(12):2884-2886.

doi: 10.3324/haematol.2025.288065. Epub 2025 Jun 19.

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Hematology, Faculty of Medicine, University of Toronto, Toronto, ON.
² Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Hematology, Faculty of Medicine, University of Toronto, Toronto, ON. dr.dennis.kim@uhn.ca.

No abstract available

References

1. Zhang X, Yang Y, Liu B, et al. Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia. Haematologica. 2025;110(12):2986-2996. - PMC - PubMed
1. Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15(1):113. - PMC - PubMed
1. U.S. Food and Drug Administration. Dose Optimization Guidance. 2023.
1. Copland M. Is there a role for dose modification of TKI therapy in CML? Curr Hematol Malig Rep. 2019;14(4):337-345. - PMC - PubMed
1. Fassoni AC, Baldow C, Roeder I, Glauche I. Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data. Haematologica. 2018;103(11):1825-1834. - PMC - PubMed